Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
for Acute Leukemia of Ambiguous Lineage
Drug: Venetoclax
110 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: Up to 365 Days
Code: NCT06317662·Phase 2·Recruiting